Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Qkine Limited and Akron Bio Announce Strategic Partnership

January 27, 2026 By BioInformant Team Leave a Comment

Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics

Cambridge, UK and Boca Raton, FL – January 27, 2026 – Qkine Limited, a leading innovator in the development of high-quality growth factors and cytokines, and Akron Bio, a leading supplier of critical materials and services to the cell and gene therapy industry, today announced a strategic partnership focused on the joint development and global supply of ancillary materials to enable the development of stem cell-based therapeutics. [Read more…]

CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis

January 22, 2026 By BioInformant Team Leave a Comment

Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]

Novo Nordisk Foundation Commits DKK 5.5 Billion to the BioInnovation Institute (BII) through 2035

January 19, 2026 By BioInformant Team Leave a Comment

In a strategic move set to reshape the European biotech and science innovation landscape, the Novo Nordisk Foundation has pledged a long-term investment of up to DKK 5.5 billion (≈ €736 million) to the Copenhagen-based BioInnovation Institute (BII), extending support through 2035. This unprecedented investment will expand BII’s role in commercializing science, scaling startups, and building cross-sector bridges across Europe.

The commitment also signals a broader push to close Europe’s long-standing gap between world-class research and global commercial leadership in emerging technologies. [Read more…]

Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture and Commercialize Cytora’s Allogeneic Stem Cell Therapy in U.S.

January 15, 2026 By BioInformant Team Leave a Comment

Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot Ulcers and Other Indications

PRINCETON, N.J. and DAVIE, Fla. and TEL AVIV, Israel, Jan. 7, 2026 – Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO); and Zeo ScientifiX, Inc. (Zeo), a Florida-based clinical-stage biopharmaceutical company specializing in research, clinical trials, manufacturing and the commercialization, and market access of biologics, today announced a comprehensive strategic partnership to advance and commercialize Cytora’s novel allogeneic, off- the- shelf, human oral mucosal stem cell therapy in the United States. [Read more…]

Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience

January 15, 2026 By BioInformant Team Leave a Comment

CARLSBAD, Calif. – Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”). Generation of the line marks a successful milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. [Read more…]

« Previous Page
1
…
4
5
6
7
8
…
144
Next Page »